Sanbio Inc., of Mountain View, Calif., presented safety and efficacy data from its ongoing phase I/IIa trial of SB623 cell therapy in patients with chronic stroke disability at the International Stroke Conference in San Diego. The data presented demonstrated that the clinical outcome results showing benefit on all three stroke scales were highly significant at six, nine and 12 months post-treatment. There have been no serious adverse events attributable to the cell-therapy product, Sanbio said.